Implemed Olimpicc antimicrobial CVC catheter study gets funding from AmHS/Premier/SunHealth.
This article was originally published in The Gray Sheet
Executive Summary
IMPLEMED OLIMPICC ANTIMICROBIAL CENTRAL VENOUS CATHETER TRIALS are slated to begin during the next several weeks, the company says. Implemed received an investigational device exemption Dec. 8 to study the peripherally inserted catheter's antimicrobial performance, as well as its general safety and efficacy, the firm says.